

Participants With Drug-Related Adverse Events  
Weeks 0 to 12  
All Participants as Treated

	Placebo		Xanomeline Low Dose		Xanomeline High Dose		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Participants in population	xx		xx		xx		xxx	
with one or more drug-related adverse events	xx	(xx.x)	xx	(xx.x)	xx	(xx.x)	xxx	(xx.x)
with no drug-related adverse events	xx	(xx.x)	xx	(xx.x)	xx	(xx.x)	xx	(xx.x)
Cardiac disorders	x	(x.x)	x	(x.x)	x	(x.x)	xx	(x.x)
Atrial fibrillation	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Atrial flutter	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Atrioventricular block first degree	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Atrioventricular block second degree	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Bradycardia	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Bundle branch block right	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Cardiac failure congestive	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Myocardial infarction	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Palpitations	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Sinus arrhythmia	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Sinus bradycardia	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Supraventricular extrasystoles	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Ventricular extrasystoles	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Wolff-parkinson-white syndrome	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
Congenital, familial and genetic disorders	x	(x.x)	x	(x.x)	x	(x.x)	x	(x.x)
<p>Every participant is counted a single time for each applicable row and column.</p> <p>A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.</p> <p>Adverse event terms are from MedDRA Version 24.0.</p>								

Source: [CDISCpilot: adam-adsl; adae]